Equities
  • Price (EUR)19.16
  • Today's Change-0.58 / -2.94%
  • Shares traded40.56k
  • 1 Year change-25.88%
  • Beta0.6103
Data delayed at least 15 minutes, as of Mar 09 2026 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.

  • Revenue in EUR (TTM)51.78m
  • Net income in EUR-169.77m
  • Incorporated2012
  • Employees245.00
  • Location
    Formycon AGFraunhoferstrasse 15, PlaneggMARTINSRIED 82152GermanyDEU
  • Phone+49 89 864667100
  • Fax+49 89 864667110
  • Websitehttps://www.formycon.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Selvita SA87.55m-677.62k175.78m434.00--2.3714.222.01-0.1577-0.157720.3717.230.59838.964.97398,187.40-0.46295.76-0.57157.3380.2780.65-0.77378.570.88230.75380.3757---1.73---108.73------
Diamyd Medical AB32.65k-17.12m180.00m41.00--8.50--5,513.88-1.52-1.520.00291.680.0013--18.818,923.08-69.46-44.47-76.54-49.74-----52,430.46-31,802.45----0.1628--0.00-17.54-11.81--38.40--
Saniona AB40.75m26.70m186.19m34.006.903.136.814.572.082.083.324.600.8522--44.7912,776,440.0055.85-14.5465.47-17.3178.8427.4165.53-30.17----0.00--29.80121.2350.85--71.22--
Egetis Therapeutics AB (publ)5.86m-32.14m207.59m40.00--6.53--35.41-0.9237-0.92370.16980.85710.087330.363.601,562,500.00-47.87-39.01-69.47-46.6819.8461.77-548.16-577.701.04-35.790.1951--35.368.940.3201--128.65--
Sensorion SA0.00-28.09m215.25m68.00--2.21-----0.0931-0.09310.000.18950.00----0.00-32.12-34.53-38.36-43.50------------0.0265-------17.72--98.90--
Transgene SA7.24m-36.78m218.25m147.00------30.15-0.1456-0.14560.0618-0.02720.1578--8.7243,872.73-80.19-33.32-186.71-40.55-----508.10-251.37---17.281.13---20.34-14.48-52.15--12.68--
Oryzon Genomics SA0.00-2.61m222.09m44.00--1.83-----0.0381-0.03810.001.520.00516.83--0.00-2.05-3.45-2.30-3.94--------1.94-29.950.0608------27.18--3.55--
Eurobio Scientific SA162.09m2.36m230.60m380.0095.911.2512.941.420.23460.234615.7618.030.56511.625.21497,196.300.823114.001.0217.3723.6951.401.4620.701.251.720.08450.0018.8921.21-17.314.8615.38--
Cellectis SA70.94m-30.38m234.66m224.00--2.73--3.31-0.3029-0.30290.70531.190.2234--8.58316,715.80-9.57-21.50-16.65-29.24---32.79-42.82-220.86---3.130.5013--435.3716.4466.41---21.58--
Vicore Pharma Holding AB358.06k-44.79m259.86m37.00--2.53--725.76-1.99-1.990.01593.890.0032--0.2708103,162.20-39.42-46.68-42.79-51.50-----12,509.14-1,362.60---18.03-----96.51---183.14------
Hansa Biopharma AB20.85m-49.65m280.08m125.00------13.43-6.44-6.442.73-0.82680.22619.122.241,778,120.00-53.80-57.18-81.36-73.2262.4160.32-238.12-464.701.92--1.10--29.74105.2834.44------
Avacta Group Plc-12.80m-38.20m330.48m151.00--1,777.08-----0.0891-0.1579-0.02980.0004-0.1872-----73,456.95-55.83-43.48-129.38-78.27--63.54---781.440.7883-0.48370.993---96.04---0.9503------
Formycon AG51.78m-169.77m338.09m245.00--0.8289--6.53-9.60-9.602.9323.120.061331.721.91207,112.00-20.09-1.47-21.17-1.58-0.992725.54-327.88-13.001.51-1.270.0244---10.3215.48-265.81--96.87--
Puretech Health PLC5.49m43.55m340.51m56.007.911.0511.2262.010.15420.15420.01971.160.0113--2.8184,945.525.63-3.276.57-3.83----498.87-253.25----0.0537--44.98-13.21181.45-33.81-75.53--
Newron Pharmaceuticals SpA60.06m25.40m405.70m22.0014.28245.8515.866.751.231.232.810.07171.39--11.692,461,206.0058.67-23.70123.93-32.0598.1797.1442.30-69.33--8.560.9708--467.4148.83197.65---23.92--
Genfit SA45.41m-38.76m445.08m188.00--8.48--9.80-0.7737-0.77370.90831.050.2207519.750.9236252,277.80-18.84-7.73-23.25-9.7995.4295.68-85.35-37.153.74-10.870.1223--85.8211.61105.22---13.57--
Data as of Mar 09 2026. Currency figures normalised to Formycon AG's reporting currency: Euro EUR

Institutional shareholders

7.14%Per cent of shares held by top holders
HolderShares% Held
Active Ownership Corp SARLas of 30 Jun 20251.07m6.04%
American Century Investment Management, Inc.as of 05 Feb 202644.76k0.25%
Paladin Asset Management Investmentaktiengesellschaft TGVas of 30 Jun 202543.88k0.25%
GS&P Kapitalanlagegesellschaft SAas of 30 Jun 202532.50k0.18%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 29 Aug 202526.00k0.15%
Proaktiva GmbHas of 30 Dec 202516.00k0.09%
HANSAINVEST Hanseatische Investment-GmbHas of 31 Dec 202511.55k0.07%
NFS Netfonds Financial Service GmbHas of 31 Dec 20259.58k0.05%
Spirit Asset Management SAas of 30 Jun 20255.25k0.03%
Goyer & G�ppel KGas of 30 Jan 20265.00k0.03%
More ▼
Data from 30 Jun 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.